Sullivan Christopher Ryan
Known title: Chief Financial OfficerCIK: 0001810417
Sullivan Christopher Ryan's purchase track record
Sullivan Christopher Ryan has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/9/2023 | AVTX | $2K | -97.7% | -98.7% | +7.1% |
| 12/10/2021 | AVTX | $1K | -63.2% | -75.1% | -17.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AVTX | ▲ Buy | Option Exercise | 12,394 | $122K | 9/16/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 12,394 | $202K | 9/16/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 10,185 | $82K | 9/10/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 10,185 | $179K | 9/10/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 31,031 | $307K | 8/18/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 31,031 | $622K | 8/18/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 37,945 | $375K | 8/17/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 2,876 | $28K | 8/17/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 37,945 | $753K | 8/17/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 3,749 | $75K | 8/17/2026 | View on chart |
| AVTX | ▼ Sell | Tax Withholding | 138 | $2K | 6/10/2026 | View on chart |
| AVTX | ▲ Buy | Grant | 39,900 | $0 | 5/21/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 18,606 | $184K | 5/7/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 18,606 | $449K | 5/7/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 47,000 | $378K | 5/6/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 13,834 | $257K | 5/6/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 12,347 | $238K | 5/6/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 2,700 | $56K | 5/6/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 9,219 | $197K | 5/6/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 8,900 | $201K | 5/6/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 8,457 | $112K | 4/30/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 8,458 | $111K | 4/29/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 1,780 | $31K | 4/2/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 6,200 | $106K | 4/2/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 500 | $8K | 4/1/2026 | View on chart |
| AVTX | ▼ Sell | Open Market | 7,479 | $126K | 4/1/2026 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 24,200 | — | 3/28/2026 | View on chart |
| AVTX | ▼ Sell | Tax Withholding | 8,241 | $114K | 3/28/2026 | View on chart |
| AVTX | ▼ Sell | Tax Withholding | 155 | $636 | 12/10/2025 | View on chart |
| AVTX | ▲ Buy | Option Exercise | 24,200 | — | 3/28/2025 | View on chart |
| AVTX | ▼ Sell | Tax Withholding | 7,285 | $62K | 3/28/2025 | View on chart |
| AVTX | ▲ Buy | Open Market | 511 | $2K | 6/9/2023 | View on chart |
| AVTX | ▲ Buy | Open Market | 955 | $1K | 12/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program
Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program. Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.